1,222 research outputs found
700 logements à Aïn-El-Turck (suite)
No full textBlancard de Lery Georges, Binoux Jacques, Folliasson Michel, Mauri Marcel Joseph, Pons D. R., Jaubert Amédée, Guth Pierre Jean, Sergent , Roman Diégo Thadée Rémy, Mialy Victor. 700 logements à Aïn-El-Turck (suite). In: Chantiers. Revue illustrée de la construction en Afrique du Nord, N°34, 1960. Le Grand Alger. pp. 11-13
Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients
No full textAim To perform a nonlinear mixed effect modelling (NONMEM) population pharmacokinetic analysis of meloxicam plasma concentrations in rheumatoid arthritis (RA) patients participating in three clinical trials, and to evaluate the effects of age, weight, gender and concomitant medications on meloxicam pharmacokinetics. Methods Meloxicam was administered to RA patients once daily for 3 weeks or 6 months at doses between 7.5 and 60 mg. Plasma samples were obtained at least 7 days after the first dose and meloxicam plasma concentrations were quantified by h.p.l.c.. Results NONMEM analysis was conducted on plasma samples derived from 586 patients. A one-compartmental model was found to describe the data adequately. For a typical subject in the population, a clearance of 0.377 l h(-1) (95% confidence interval (CI) 0.0304-0.449) in males and 0.347 l h(-1) (95% CI 0.274-0.419) in females was obtained. The volume of distribution was estimated to be 14.9 l. The findings were corroborated by subsequent analysis using WinBUGS. Analysis of covariates showed that age and gender both significantly (P < 0.005) affected clearance. The effect of age was relatively small and a dose adjustment of <10% was deemed unnecessary. Differences between males and females were attributed to differences in weight. No clinically relevant drug-drug interactions were found, although sulphasalazine and glucocorticoids both significantly (P < 0.005) affected meloxicam clearance (+19% and - 12%, respectively). The mechanisms by which these agents affect meloxicam clearance remain to be elucidated. Conclusions The population pharmacokinetic meloxicam data from patients with RA gave similar results to those obtained from phase I trials. However, uncommon drug interactions may not be detected in phase I trials because of the small number of observations made
Is cow’s milk harmful to a child’s health?
No full textDiscussions and debates have recently emerged on the potential positive and
negative effects of cow’s milk in the paediatric community, also under the
pressure of public opinion. The negative effects of cow’s-milk consumption
seem to be limited to iron status up to 9 to 12 months; then no negative
effects are observed, provided that cow’s milk, up to a maximum daily
intake of 500 mL, is adequately complemented with iron-enriched foods.
Lactose intolerance can be easily managed and up to 250 mL/day of milk can
be consumed. Allergy to cow’s-milk proteins is usually transient. Atopic
children may independently be at risk for poor growth, and the contribution
of dairy nutrients to their diet should be considered. The connection of cow’s
milk to autistic spectrum disorders is lacking, and even a cause–effect
relation with type 1 diabetes mellitus has not been established because many
factors may concur. Although it is true that cow’s milk stimulates insulinlike
growth factor-1 and may affect linear growth, association with chronic
degenerative, noncommunicable diseases has not been established. Finally,
fat-reduced milk, if needed, should be considered after 24 to 36 months.
Cow’s milk represents a major source of high nutritional quality protein as
well as of calcium. Moreover, it has growth-promoting effects independent
of specific compounds. Its protein and fat composition, together with the
micronutrient content, is suggestive of a functional food, whose positive
effects are emphasised by regular consumption, particularly under conditions
of diets poor in some limiting nutrients, although in industrialised
countries cow’s milk’s optimal daily intake should be around 500 mL,
adequately complemented with other relevant nutrient
Officers examining traffic tickets fines scattered by Mansfield Mayor Roland A. Turck
No full textOfficers examine the traffic tickets and traffic fines scattered by Mansfield Mayor Roland A. Turck as he crouched along the wooden counter in the Municipal Building, dodging bullets fired, he said, by City Secretary J. D. Hayes. Left to right are Sheriff Wright, Mansfield Constable Tom Beard and Sheriff\u27s Deputy Bob Morton.https://mavmatrix.uta.edu/specialcollections_startelegram1950s/1076/thumbnail.jp
Characterization of membrane-bound small GTP-binding proteins from Nicotiana tabacum
No full textHaizel T, Merkle T, Turck F, Nagy F. Characterization of membrane-bound small GTP-binding proteins from Nicotiana tabacum. Plant Physiology. 1995;108(1):59-67
Correction: Comment on “Relation of fruit juice with adiposity and diabetes depends on how fruit juice is defined: a re-analysis of the EFSA draft scientific opinion on the tolerable upper intake level for dietary sugars” by Chen et al. 2023 (European Journal of Clinical Nutrition, (2023), 77, 12, (1176-1177), 10.1038/s41430-023-01337-0)
No full textCorrection to: European Journal of Clinical Nutrition , published online 15 September 2023 The following disclaimer was added in the article backmatter: “The authors Silvia VALTUEÑA MARTINEZ and Ionut CRACIUN are employed with the European Food Safety Authority (EFSA) in NIF Unit that provides scientific and administrative support to the EFSA NDA Panel in the area of nutrition. However, the present article is published under the sole responsibility of the authors and may not be considered as an EFSA scientific output. The positions and opinions presented in this article are those of the authors alone and do not necessarily represent any official position of EFSA. To know about the views or scientific outputs of EFSA, please consult its website under.” The original article has been corrected
Comment on “Relation of fruit juice with adiposity and diabetes depends on how fruit juice is defined: a re-analysis of the EFSA draft scientific opinion on the tolerable upper intake level for dietary sugars” by Chen et al. 2023
No full textScientific and technical assistance to the evaluation of the safety of calcidiol monohydrate as a novel food
No full textEFSA was asked by the European Commission to provide scientific assistance with respect to the EFSA adopted scientific opinion on ‘Safety of calcidiol monohydrate produced by chemical synthesis as a novel food pursuant to Regulation (EU) 2015/2283’, including its bioavailability as a metabolite of vitamin D3 when added for nutritional purposes to food supplements. On 5 July 2023, EFSA adopted the ‘Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate’. This opinion concerns an updated exposure assessment for vitamin D and proposes a conversion factor for calcidiol monohydrate into vitamin D3 of 2.5 for labelling purposes. In addition, in reference to the EFSA opinion on the safety of calcidiol monohydrate, the Commission had received a letter from the pharmaceutical company EirGen Pharma Ltd requesting a revision of this opinion based on new data concerning calcidiol. Based on the information and data considered in this scientific technical report, EFSA concludes that the novel food calcidiol monohydrate proposed for use in food supplements is a bioavailable source of the biologically active metabolite of vitamin D, i.e. 1,25-dihydroxyvitamin D, that a conversion factor of 2.5 reflects the relative bioavailability of calcidiol vs vitamin D3 under the proposed conditions of use and use levels, and that it is safe under the proposed conditions of use and use levels, i.e. up to 10 μg/day for children ≥ 11 years old and adults, including pregnant and lactating women, and up to 5 μg/day for children 3–10 years of age
RETRACTED: Feudal Multiagent Reinforcement Learning for Interdomain Collaborative Routing Optimization
No full textThis work was supported by the National Key R&D Program of China (Grant No. 2018YFB1800100); the National Natural Science Foundation of China (Grant No. U1909204); the Beijing Natural Science Foundation, China (Grant No. 4202082); and the Open Research Projects of Zhejiang Lab (Grant No. 2021LC0AB03)
- …
